{"slideshow_credits": null, "snippet": "Xtandi, which was developed by Medivation and Astellas Pharma, was shown to extend the life of men with late-stage cancer by nearly five months.", "abstract": "Food and Drug Administration approves a new life-prolonging drug for men with late-stage prostate cancer, adding to an increasingly crowded field; new drug, called Xtandi, was developed by small pharmaceutical company Medivation in partnership with Astellas Pharma.", "section_name": "Business Day", "print_page": "3", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2012/09/01/business/fda-approves-prostate-cancer-drug.html", "lead_paragraph": "Xtandi, which was developed by Medivation and Astellas Pharma, was shown to extend the life of men with late-stage cancer by nearly five months.", "headline": {"seo": "F.D.A. Approves Prostate Cancer Drug", "main": "New Drug For Prostate Cancer Gets F.D.A. Nod", "print_headline": "New Drug For Prostate Cancer Gets F.D.A. Nod"}, "_id": "53fa6d4738f0d8431914d7c3", "word_count": "637", "multimedia": [], "pub_date": "2012-09-01T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Food and Drug Administration", "name": "organizations", "is_major": "N", "rank": "1"}, {"value": "Prostate Cancer", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "3"}, {"value": "Medivation Inc", "name": "organizations", "is_major": "Y", "rank": "4"}, {"value": "Astellas Pharma", "name": "organizations", "is_major": "Y", "rank": "5"}], "blog": [], "subsection_name": null, "type_of_material": "News"}